During the recent session, Soleno Therapeutics Inc (NASDAQ:SLNO)’s traded shares were 1.04 million, with the beta value of the company hitting -2.25. At the last check today, the stock’s price was $70.42, reflecting an intraday gain of 4.49% or $3.03. The 52-week high for the SLNO share is $72.96, that puts it down -3.61 from that peak though still a striking 48.01% gain since the share price plummeted to a 52-week low of $36.61. The company’s market capitalization is $3.23B, and the average intraday trading volume over the past 10 days was 2.44 million shares, and the average trade volume was 820.59K shares over the past three months.
Soleno Therapeutics Inc (SLNO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.11. SLNO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Soleno Therapeutics Inc (NASDAQ:SLNO) trade information
Soleno Therapeutics Inc (SLNO) registered a 4.49% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.49% in intraday trading to $70.42, hitting a weekly high. The stock’s 5-day price performance is 43.38%, and it has moved by 56.51% in 30 days. Based on these gigs, the overall price performance for the year is 63.00%. The short interest in Soleno Therapeutics Inc (NASDAQ:SLNO) is 4.99 million shares and it means that shorts have 8.63 day(s) to cover.
The consensus price target of analysts on Wall Street is $74, which implies an increase of 4.84% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $70 and $81 respectively. As a result, SLNO is trading at a discount of -15.02% off the target high and 0.6% off the low.
Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 2.58M by the end of current fiscal year.
SLNO Dividends
Soleno Therapeutics Inc is due to release its next quarterly earnings on 2025-Feb-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Soleno Therapeutics Inc (NASDAQ:SLNO)’s Major holders
Soleno Therapeutics Inc insiders own 2.93% of total outstanding shares while institutional holders control 113.72%, with the float percentage being 117.16%. VIVO CAPITAL, LLC is the largest shareholder of the company, while 220.0 institutions own stock in it. As of 2024-06-30, the company held over 7.32 million shares (or 18.9401% of all shares), a total value of $298.53 million in shares.
The next largest institutional holding, with 4.07 million shares, is of CARLYLE GROUP INC.’s that is approximately 10.5395% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $166.36 million.
Also, the Mutual Funds coming in first place with the largest holdings of Soleno Therapeutics Inc (SLNO) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund. Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.13 shares. This amounts to just over 2.46 percent of the company’s overall shares, with a $78.95 million market value. The same data shows that the other fund manager holds slightly less at 933.3, or about 2.04% of the stock, which is worth about $65.3 million.
